Vivozon Completes Final Dosing in Korean Phase 2 Trial of VVZ-2471 for Postherpetic Neuralgia

Vivozon, an affiliate of Vivozon Pharmaceutical, said on the 12th that it completed dosing for the final subject in a Korean Phase 2 clinical trial of its oral non-opioid analgesic candidate, VVZ-2471, in patients with postherpetic neuralgia (PHN). The domestic Phase 2 study is evaluating VVZ-2471 in PHN patients. Postherpetic neuralgia is known as neuropathic pain that persists after shingles, and the company has been developing the candidate as an oral non-opioid pain treatment. Completion of final subject dosing means a key procedure in this clinical stage has been finished, with attention now turning to the process of confirming results. Source: mk.co.kr.